Compare YJ & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YJ | XCUR |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3M | 13.7M |
| IPO Year | 2019 | 2017 |
| Metric | YJ | XCUR |
|---|---|---|
| Price | $1.85 | $1.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 63.4K |
| Earning Date | 03-27-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.11 | $1.18 |
| 52 Week High | $13.97 | $9.48 |
| Indicator | YJ | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 52.79 | 32.68 |
| Support Level | $1.38 | N/A |
| Resistance Level | $13.97 | $2.02 |
| Average True Range (ATR) | 1.20 | 0.13 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 5.59 | 20.63 |
Yunji Inc is a social e-commerce platform in China using a membership-based model that leverages the power of social interaction. The group offers high-quality products at attractive prices and incentivizes members to promote its platform and share products with their social contacts. It empowers prime emerging brands and manufacturers with a deep understanding of market trends and customer behavior to produce high-quality products to meet the demands of members. The company also developed several private labels in the mass consumption field, which are sold on its own platform as well as offered and sold through external channels. It operates in the PRC, and substantially all the Group's revenue is derived from within the PRC.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.